AbCellera (NASDAQ: ABCL) operates as an antibody discovery and development engine. It uses its proprietary technology platform to develop therapeutic antibodies against a wide range of diseases, including cancer, infectious diseases, and autoimmune disorders. The company was founded in 2012 and is based in Vancouver, Canada.
AbCellera's Product Videos
AbCellera's Products & Differentiators
AbCellera Lead Panel
10 antibody sequences for development. Down-selected from diverse panels of antibodies based on: · Small-scale expression · Binding validation · Functional validation · High-throughput developability
Research containing AbCellera
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned AbCellera in 2 CB Insights research briefs, most recently on Aug 29, 2023.
Expert Collections containing AbCellera
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
AbCellera is included in 4 Expert Collections, including Artificial Intelligence.
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
Digital Health 50
The winners of the second annual CB Insights Digital Health 150.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Drug Discovery Tech Market Map
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
AbCellera has filed 5 patents.
Immunology, Animal virology, Epidemiology, Animal viral diseases, Clusters of differentiation
Immunology, Animal virology, Epidemiology, Animal viral diseases, Clusters of differentiation
Latest AbCellera News
Nov 30, 2023
AbCellera cuts 10 per cent of staff as biotech slump hits Vancouver antibody developer Share AbCellera Biologics Inc. ABCL-Q has cut 10 per cent of its staff, joining a growing list of biotechnology companies that are reducing jobs as they face a prolonged sector slump. The company cut 63 jobs, mostly in Vancouver where it is based, as it shifts its focus away from discovering antibody drugs for other pharmaceutical companies – it has 110 such programs under way with 42 partners – and toward developing its own treatments. Earlier this month, AbCellera revealed its first two such molecules: one for atopic dermatitis, and the other for an undisclosed metabolic and endocrine condition. But with the biotechnology market in deep bear territory – AbCellera’s stock has shed two-thirds of its value in the past two years – the company decided to cut staff in response to “the quite bleak macroeconomic environment,” said chief executive officer Carl Hansen in an interview. “We’re making sure we’re putting resources and people on things that will matter most to the business in the long run.” AbCellera is in “fantastic” financial condition, Mr. Hansen added, with more than US$1-billion in total available liquidity after a long period of investing in technology, people and facilities, and enough cash for three-plus years. “We’re trying to build something pretty awesome here, and we need to make sure we have only things that really matter that are being resourced.” The last biotech downturn lasted six years until 2014, “and we’re arranging our plan that if that happens again, we’re masters of our fate.” Bloom Burton analyst David Martin said that, given AbCellera’s shifting strategy, it “was probably overweight on discovery scientists. AbCellera is certainly not alone with layoffs in the biotech sector as it prioritizes programs that should be of the highest value.” AbCellera had been on a rapid pace of growth , hiring more than 500 people since it went public nearly three years ago after rapidly discovering an antibody to treat hospitalized COVID-19 patients using its complex technology platform. Development partner Eli Lilly & Co. got emergency authorization to take the drug and a follow-up treatment to market without having to undergo years of human trials, which netted about US$1-billion in sales royalties for AbCellera. Its IPO smashed records, bringing in more than US$550-million from investors, and its market capitalization after its first day of trading was US$15.7-billion – more than George Weston Ltd. and Imperial Oil Ltd. at the time. The company is set to move into a new headquarters in Vancouver’s Mount Pleasant neighbourhood in March, consolidating its operations after taking up residence in five buildings in the area. It is also building an advanced manufacturing and advanced clinical research facility in the city – a $700-million project that the federal and B.C. governments are supporting with $300-million in funding. But investor interest has worn off because of the sector’s slump and the end of COVID-related revenue boom. Biotech companies typically wait a decade for drugs they develop to generate royalties; most drugs don’t make it, and most biotech companies either die, start over or are bought by pharma giants long before then. Mr. Hansen, meanwhile, remains determined to build AbCellera into Canada’s first homegrown pharmaceutical giant. That ambitious project carries high risks and could take a decade to come to fruition if everything goes well. AbCellera’s numerous partnerships aren’t expected to yield royalties for years, and it plans to limit future partnerships to drugs where it can generate greater returns. As for its own drugs, those would likely take years to get to market and require AbCellera to raise hundreds of millions of dollars apiece to advance them through research and development if they show promise. The few areas untouched by layoffs, Mr. Hansen noted, are more advanced areas, included manufacturing, preclinical and clinical development, where the company plans to continue hiring. Mr. Hansen co-founded AbCellera 11 years ago, spinning it out of a cross-disciplinary lab at University of British Columbia where he taught. Its platform combines data science, protein engineering, machine learning, bioinformatics and genomics to rapidly test antibodies from humans or animals that develop an immune response to diseases, and to determine which could become drugs. The company’s ability to unearth antibodies quicker and cheaper than conventional methods helped it land a contract in 2018 with the U.S. Defence Department’s Defense Advanced Research Projects Agency to explore rapid medical responses to pandemics after the H1N1 outbreak. AbCellera was subsequently well positioned to show off its potential early in the COVID-19 pandemic, and made it an industrial champion for the federal government, which has committed more than $400-million in funding to the company.
AbCellera Frequently Asked Questions (FAQ)
When was AbCellera founded?
AbCellera was founded in 2012.
Where is AbCellera's headquarters?
AbCellera's headquarters is located at 2215 Yukon Street, Vancouver.
What is AbCellera's latest funding round?
AbCellera's latest funding round is IPO.
How much did AbCellera raise?
AbCellera raised a total of $247.07M.
Who are the investors of AbCellera?
Investors of AbCellera include DCVC, Peter Thiel, Viking Global Investors, Founders Fund, OrbiMed Advisors and 12 more.
Who are AbCellera's competitors?
Competitors of AbCellera include Abveris and 6 more.
What products does AbCellera offer?
AbCellera's products include AbCellera Lead Panel and 1 more.
Who are AbCellera's customers?
Customers of AbCellera include Eli Lilly, Novartis, IGM Biosciences, Denali Therapeutics and Empirico.
Compare AbCellera to Competitors
Arctoris develops an automated drug discovery company. It combines its unique automation platform, Ulysses, with advanced machine learning approaches and a team of seasoned drug hunters to guide and progress drug discovery programs in oncology and neurology. It offers on-demand access to various drug discovery assays conducted by robotics to biotech companies, pharmaceutical corporations, and academic centers. It was founded in 2016 and is based in Oxfordshire, United Kingdom.
Solidus Biosciences is a company focused on providing business intelligence in the pharmaceutical and biologic drugs sector. The company's main services include offering insights on life cycle management, brand erosion, generic entry, biosimilars, patents, sales, litigation, and more, all related to pharmaceutical and biologic drugs. The company primarily serves the biopharmaceutical industry. It is based in Troy, New York.
Oxford BioTherapeutics is a clinical stage oncology company that operates in the healthcare and biotechnology sectors. The company primarily focuses on the development of first-in-class immune therapies and antibody-drug conjugates, which are designed to improve outcomes for cancer patients, particularly those who respond poorly to PD-1 inhibitors. These therapies work by re-engaging the patient's immune system and directly targeting cancer cells. It is based in Oxfordshire, England.
NeuroGenomeX is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in animal models of traumatic brain injury (TBI).
SBIO is focused on the discovery and development of small molecule oncology drugs.
NeoClone is a custom monoclonal antibody company focused on developing high quality antibodies for sale as reagents and establishing partnerships and collaborations to develop diagnostic mAbs.